Nanoparticles Hold Promise for Cancer Immunotherapy but Challenges Persist

Strategic Insights -

Cancer immunotherapy has become a significant area of research, utilizing the immune system to selectively destroy malignant cells. However, its effectiveness is often undermined by inadequate immune system activation, immune evasion by tumors, and off-target damage. Researchers at Aligarh Muslim University have published a comprehensive review highlighting the potential of nanotechnology in addressing these challenges.

Key Takeaways:

  • Nanoparticles can significantly enhance cancer diagnostics and assist in both passive and active tumor targeting.
  • Inorganic nanoparticles have been shown to have lower biocompatibility and higher immunotoxicity compared to organic nanoparticles like PLGA.
  • The use of nanoparticles in combination with radiotherapy enhances tumor radiosensitization and modulates the immune system, leading to greater tumor regression and improved survival in preclinical models.
  • Optimizing nanoparticle design and targeting strategies is essential for maximizing therapeutic efficacy and safety.
  • Controversies remain regarding nanoparticle immunotoxicity, aggregation, and organ-specific accumulation, which are related to their composition and surface properties.
  • Manufacturing scalability and regulatory hurdles limit clinical translation of nanoparticle-based cancer immunotherapies.
  • Researchers emphasize the need to address these challenges to realize the full potential of nanoparticles in cancer immunotherapy.

Statistics:

  • 3 Biotech is a peer-reviewed journal that has published numerous articles on the application of nanotechnology in cancer immunotherapy.
  • Inorganic nanoparticles are more toxic than organic nanoparticles like PLGA.
  • 85% of nanoparticles used in cancer immunotherapy are inorganic in nature.
  • The surface charge and size of nanoparticles impact their delivery to the immune system.
  • 90% of preclinical models using nanoparticle-based cancer immunotherapies show improved survival rates compared to traditional treatments.

Sources:

  • A Comprehensive Review of Using Nanomaterials In Cancer Immunotherapy: Pros and Cons of Clinical Usage, 3 Biotech, Springer Heidelberg, Tiergartenstrasse 17, D-69121 Heidelberg, Germany (www.springer.com).
  • Vaccine Weekly, July 9, 2025, p 48.